Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.

Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y, Do ZN, Mehra U, Tran V, Vincelette J, Waszczuk J, White K, Wong KR, Zhang LN, Jones PD, Hammock BD, Patel DV, Whitcomb R, MacIntyre DE, Sabry J, Gless R.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):983-8. doi: 10.1016/j.bmcl.2010.12.042. Epub 2010 Dec 13.

2.

Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.

Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD.

Clin Sci (Lond). 2009 Jan;116(1):61-70. doi: 10.1042/CS20080039.

3.

Soluble epoxide hydrolase: a novel therapeutic target in stroke.

Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ.

J Cereb Blood Flow Metab. 2007 Dec;27(12):1931-40. Epub 2007 Apr 18.

4.

Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.

Honetschlägerová Z, Husková Z, Vaňourková Z, Sporková A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Červenka L, Kopkan L.

J Physiol. 2011 Jan 1;589(Pt 1):207-19. doi: 10.1113/jphysiol.2010.199505.

5.

Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.

Kato Y, Fuchi N, Saburi H, Nishimura Y, Watanabe A, Yagi M, Nakadera Y, Higashi E, Yamada M, Aoki T.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5975-9. doi: 10.1016/j.bmcl.2013.08.054. Epub 2013 Aug 20.

PMID:
24035338
6.

Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.

Zhang LN, Vincelette J, Chen D, Gless RD, Anandan SK, Rubanyi GM, Webb HK, MacIntyre DE, Wang YX.

Eur J Pharmacol. 2011 Mar 1;654(1):68-74. doi: 10.1016/j.ejphar.2010.12.016. Epub 2010 Dec 25.

PMID:
21187082
7.

Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.

Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I.

Hypertension. 2005 Apr;45(4):759-65. Epub 2005 Feb 7.

8.

Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.

Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, Patel DV, Anandan SK, Gless R, Webb HK.

J Clin Pharmacol. 2012 Mar;52(3):319-28. doi: 10.1177/0091270010397049. Epub 2011 Mar 21.

PMID:
21422238
9.

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Wang S, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Chen X, Zhang B, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3398-404. doi: 10.1016/j.bmcl.2009.05.036. Epub 2009 May 18.

PMID:
19481932
10.

Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.

Burmistrov V, Morisseau C, Lee KS, Shihadih DS, Harris TR, Butov GM, Hammock BD.

Bioorg Med Chem Lett. 2014 May 1;24(9):2193-7. doi: 10.1016/j.bmcl.2014.03.016. Epub 2014 Mar 20.

11.

Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.

Roche C, Besnier M, Cassel R, Harouki N, Coquerel D, Guerrot D, Nicol L, Loizon E, Remy-Jouet I, Morisseau C, Mulder P, Ouvrard-Pascaud A, Madec AM, Richard V, Bellien J.

Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1020-9. doi: 10.1152/ajpheart.00465.2014. Epub 2015 Feb 27.

12.

Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.

Sporková A, Jíchová S, Husková Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L.

Clin Exp Pharmacol Physiol. 2014 Dec;41(12):1003-13. doi: 10.1111/1440-1681.12310.

13.

Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.

Guglielmino K, Jackson K, Harris TR, Vu V, Dong H, Dutrow G, Evans JE, Graham J, Cummings BP, Havel PJ, Chiamvimonvat N, Despa S, Hammock BD, Despa F.

Am J Physiol Heart Circ Physiol. 2012 Oct 1;303(7):H853-62. doi: 10.1152/ajpheart.00154.2012. Epub 2012 Aug 3.

14.

Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME.

Honetschlägerová Z, Kitada K, Husková Z, Sporková A, Kopkan L, Bürgelová M, Varcabová Š, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerová Z, Červenka L.

J Hypertens. 2013 Feb;31(2):321-32. doi: 10.1097/HJH.0b013e32835b50aa.

15.

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, Hammock BD.

J Med Chem. 2010 Oct 14;53(19):7067-75. doi: 10.1021/jm100691c.

16.

Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats.

Iyer A, Kauter K, Alam MA, Hwang SH, Morisseau C, Hammock BD, Brown L.

Exp Diabetes Res. 2012;2012:758614. doi: 10.1155/2012/758614. Epub 2011 Oct 10.

17.

Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.

Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Malý J, Netuka I, Ošťádal B, Červenka L.

Clin Sci (Lond). 2012 Jun;122(11):513-25. doi: 10.1042/CS20110622.

18.

Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.

Koeners MP, Wesseling S, Ulu A, Sepúlveda RL, Morisseau C, Braam B, Hammock BD, Joles JA.

Am J Physiol Endocrinol Metab. 2011 Apr;300(4):E691-8. doi: 10.1152/ajpendo.00710.2010. Epub 2011 Jan 25.

19.

Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.

Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. Epub 2006 Jul 25.

20.

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD.

Hypertension. 2005 Oct;46(4):975-81. Epub 2005 Sep 12.

Supplemental Content

Support Center